COMPANY

Sensorium Therapeutics

Sensorium Therapeutics is a clinical-stage Cambridge, MA biotech developing mechanistically novel small-molecule CNS medicines for anxiety, epilepsy and cognitive dysfunction in neurodegenerative disease, using its SensAI platform. From company website Source · Oct 12, 2026

Keywords: neuroscience CNS small molecule anxiety epilepsy natural compounds clinical-stage Cambridge, MA

Profile checked Oct 10, 2026

2NIH grants

NIH awards 2

Annual award amounts. Total $2.0M.

Apr 2, 2025 NIH award 4R44AG085858-02 FY2025: $1,517,441 awarded for that fiscal year; activity R44 (SBIR); PI BROWN, JEFFREY M.; recipient as written: SENSORIUM THERAPEUTICS INC, BOSTON, MA. A Drug Discovery Platform to Priorit source ↗
Nov 24, 2023 NIH award 1R44AG085858-01 FY2024: $502,499 awarded for that fiscal year; activity R44 (SBIR); PI BROWN, JEFFREY M.; recipient as written: SENSORIUM THERAPEUTICS INC, BOSTON, MA. A Drug Discovery Platform to Prioritiz source ↗